Shots:

• Sanofi and Evotec launches BRIDGE LAB031- designed to convert academic research into drug discovery candidates for multiple therapeutic areas. BRIDGE is a public-private partnership combining academia- biotech and venture capital into pharma for early-stage projects
• The companies will focus on development of multiple small molecule programmes through lead optimization for next three years
• Evotec will develop and generate multiple lead candidates for Sanofi and apply its technologies to the projects for expedited drug discovery and development. Sanofi has an option to acquire development rights of products on expected milestone criteria

Ref: Evotec | Image: Handelsblatt